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Objectives This study sought to perform a weighted meta-analysis to determine the rates of major outcomes after trans-
catheter aortic valve replacement (TAVR) using Valve Academic Research Consortium (VARC) definitions and to
evaluate their current use in the literature.
Background Recently, the published VARC definitions have helped to add uniformity to reporting outcomes after TAVR.
Methods A comprehensive search of multiple electronic databases from January 1, 2011, through October 12, 2011, was
conducted using predefined criteria. We included studies reporting at least 1 outcome using VARC definitions.
Results A total of 16 studies including 3,519 patients met inclusion criteria and were included in the analysis. The
pooled estimate rates of outcomes were determined according to VARC’s definitions: device success, 92.1%
(95% confidence interval [CI]: 88.7% to 95.5%); all-cause 30-day mortality, 7.8% (95% CI: 5.5% to 11.1%); myo-
cardial infarction, 1.1% (95% CI: 0.2% to 2.0%); acute kidney injury stage II/III, 7.5% (95% CI: 5.1% to 11.4%);
life-threatening bleeding, 15.6% (95% CI: 11.7% to 20.7%); major vascular complications, 11.9% (95% CI: 8.6%
to 16.4%); major stroke, 3.2% (95% CI: 2.1% to 4.8%); and new permanent pacemaker implantation, 13.9%
(95% CI: 10.6% to 18.9%). Medtronic CoreValve prosthesis use was associated with a significant higher rate of
new permanent pacemaker implantation compared with the Edwards prosthesis (28.9% [95% CI: 23.0% to
36.0%] vs. 4.9% [95% CI: 3.9% to 6.2%], p  0.0001). The 30-day safety composite endpoint rate was 32.7%
(95% CI: 27.5% to 38.8%) and the 1-year total mortality rate was 22.1% (95% CI: 17.9% to 26.9%).
Conclusions VARC definitions have already been used by the TAVR clinical research community, establishing a new standard for
reporting clinical outcomes. Future revisions of the VARC definitions are needed based on evolving TAVR clinical
experiences. (J Am Coll Cardiol 2012;59:2317–26) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.02.022Since the first transcatheter aortic valve replacement
(TAVR) case in 2002 (1), 35,000 transcatheter aortic
valve procedures have been performed worldwide. This has
resulted in a substantial number of published case series,
registries, and, lately, randomized controlled trials (2–13).
Diversity in technique and study devices as well as
disparity in the learning curve may potentially explain
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Currently, there is a growing
body of literature applying these
new VARC definitions. There-
fore, we sought to perform a
meta-analysis of all published
studies reporting outcomes using
VARC definitions after TAVR
to evaluate current acceptance
and use patterns and to deter-
mine whether future revisions are
warranted.
Methods
Studies and endpoint definitions. All studies reporting
outcomes using at least 1 VARC definition from January 1,
2011, to October 12, 2011, were selected and included in
the current analysis. Only outcomes properly reported con-
forming to VARC definitions (clear mention in the paper)
were included in the pooled analysis. Intrahospital 30-day
and 1-year outcomes are reported conforming to the VARC
definitions previously described (Online Appendix) (14).
Data source and study selection. Relevant studies were
identified through PubMed, Cochrane, and EMBASE
database searches, using the key words trans-catheter aortic
valve implantation, trans-catheter aortic valve replacement,
ercutaneous aortic valve implantation, percutaneous aortic
alve replacement, transfemoral aortic valve implantation,
transapical aortic valve implantation, transarterial aortic valve
implantation, direct aortic valve implantation, aortic stenosis,
and valve academic research consortium. Two investigators
(P.G., S.J.H.) independently reviewed the titles, abstracts,
and studies to determine whether they met the inclusion
criteria. Conflicts between reviewers were resolved by
consensus.
Statistical analysis. Outcome rates were first presented as
the minimum and maximum rates reported among se-
lected articles. Cumulative rates for each VARC outcome
were then obtained from a pooled analysis among se-
lected studies. Given the high heterogeneity among
reported rates, summary rate estimates and 95% confi-
dence intervals (CIs) were obtained using a random-
effects model, as described by DerSimonian and Laird
(15). The random-effects model was chosen for its
conservative summary estimate and incorporating both
between and within study variance. To assess heteroge-
neity across trials, we used the Cochrane Q statistic (a p
value 0.1 was considered significant). The I2 statistic
was also used to measure the consistency among studies
with values of 25%, 50%, and 75% showing, respectively,
low, moderate, and high heterogeneity.
Data collection, study selection, processing of the data,
and reporting of the results were performed according to
accepted principles related to systematic review and meta-
Abbreviations
and Acronyms
AKI  acute kidney injury
AVA  aortic valve area
CI  confidence interval
MI  myocardial infarction
TAVR  transcatheter
aortic valve replacement
TF  transfemoral
VARC  Valve Academic
Research Consortiumanalysis (16–19). The Mann-Whitney test was used tocompare proportions, with a significance level of p  0.05.
Statistical analyses were performed using SAS software
version 9.3 (SAS Institute, Cary, North Carolina).
Results
Of 482 potentially relevant articles initially screened, 16
unique studies with 3,519 patients met the inclusion criteria
and were included in the final pooled analysis (10,20–34)
(Fig. 1). A total of 1,903 Edwards Lifesciences (Irvine,
California) prosthesis (54.1%) and 1,186 Medtronic Core-
Valve (Minneapolis, Minnesota) prosthesis (33.7%) implan-
tations were identified. The type of implanted device was
not clearly reported by authors in 430 patients (12.2%).
Basic study characteristics are shown in Table 1. The 30-day
Society of Thoracic Surgeons score and logistic Euro-
SCORE were 8.7% (95% CI: 7.0% to 10.3%) and 22.8%
(95% CI: 20.3% to 25.3%), respectively. Table 2 shows the
proportion of articles that appropriately used and reported
outcomes according to VARC definitions.
In-hospital and 30-day follow-up outcomes. Overall de-
vice success reported in the literature ranged from 80% to
100%, with a pooled estimate rate of 92.1% (95% CI: 88.7%
to 95.5%) (Table 3). The most frequent modes of failure
were moderate to severe aortic regurgitation (7.4%; 95% CI:
4.6% to 10.2%), aortic valve area (AVA) 1.2 cm2 (4.8%;
95% CI: 3.0% to 6.6%), and failure of delivery or implan-
tation of the valve in the correct position (3.5%; 95% CI:
2.2% to 5.6%) (Table 4).
All-cause 30-day mortality rates were reported between
1.7% and 14.3%, with a pooled estimate of 7.8% (95% CI:
5.5% to 11.1%). Cardiovascular death accounted for most of
the 30-day mortality after TAVR, with a pooled estimate
rate of 5.6% (95% CI: 3.7% to 8.3%) (Table 3, Fig. 2).
Myocardial infarction (MI) was reported as a complica-
tion of TAVR in 0% to 5.6% of studies, with a pooled
estimate rate 1.1% (95% CI: 0.2% to 2.0%). Acute kidney
injury (AKI) at all stages was a frequent complication, with
a pooled estimate rate of 20.4% (95% CI: 16.2% to 25.8%).
However, most of the AKI was at stage I (13.3%; 95% CI:
9.8% to 18.0%), whereas the AKI at stages II/III (significant
AKI according to VARC criteria) was less frequent (7.5%;
95% CI: 5.1% to 11.4%).
Life-threatening bleeding and major vascular complica-
tions occurred at a pooled estimate rate of 15.6% (95% CI:
11.7% to 20.7%) and 11.9% (95% CI: 8.6% to 16.4%). All
neurologic events (all strokes and transient ischemic attacks)
were reported from 1.3% to 21.0% and occurred at a pooled
estimate rate of 5.7% (95% CI: 3.7% to 8.9%), and all
strokes (major and minor) were reported from 1.0% to 6.8%,
with a pooled estimate rate of 4.0% (95% CI: 2.4% to 6.3%).
The reported rates for a new permanent pacemaker implan-
tation after TAVR range from 3.4% to 50%, with a pooled
estimate rate of 13.9% (95% CI: 10.6% to 18.9%).
Medtronic CoreValve prosthesis use was associated with a
significantly higher rate of new permanent pacemaker im-
2319JACC Vol. 59, No. 25, 2012 Généreux et al.
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[95% CI: 23.0% to 36.0%] vs. 4.9% [95% CI: 3.9% to
6.2%], p  0.0001). Device-related outcomes and other
complications are shown in Table 4.
Composite endpoint and 1-year follow-up outcomes.
The 30-day safety composite endpoint was correctly re-
ported in 6 studies (37.5%) (Table 2), with a pooled
estimate rate of 32.7% (95% CI: 27.5% to 38.8%). The
1-year safety composite endpoint was reported in only 2
studies (12.5%), with a pooled estimate rate of 71.1% (95%
CI: 65.6% to 76.0%). One-year all-cause mortality and
cardiovascular mortality rates were reported in 7 studies
(43.8%) and 4 studies (25.0%), respectively, with an associ-
ated pooled estimate rate of 22.1% (95% CI: 17.9% to
26.9%) and 14.4% (95% CI: 10.6% to 19.5%).
Discussion
The current report, which includes 3,519 patients from 16
unique studies, is the first pooled analysis reporting out-
comes after TAVR according to the recently proposed
VARC definitions. The main results of the current study are
as follows: 1) VARC definitions have already been widely
used by the TAVR community since their introduction
earlier this year; 2) VARC definitions have established an
important uniformity for outcomes after TAVR; 3) the
pooled estimate outcomes after TAVR reported in this
meta-analysis represent a new standard of quality for TAVR
clinical research; 4) specific issues in the first version of the
VARC definitions were identified; and 5) refinement and
modifications of the current VARC definitions may be
Figure 1 Flow Diagram of the Study
Among the 482 potentially relevant articles, 16 were included in the final pooled aneeded and are in progress.VARC in the current literature. Since January 2011 (14),
VARC definitions have been rapidly incorporated into
clinical and research practice (Fig. 3). Although most of the
VARC-related endpoints have been reported in high pro-
portion among selected studies, the 30-day and 1-year
composite endpoints and the 1-year mortality rates have
been reported by only a few authors (Table 2). The relative
complexity of the 2 hierarchical composite endpoints, the
absence of all data fields required to compute the endpoints,
and inadequate follow-up may explain the low reporting
rates.
Not surprisingly, device-related outcomes, such as coro-
nary obstruction, ventricular septal defect, annulus rupture,
aortic rupture, aortic dissection, and left ventricle perfora-
tion, occurring less frequently after TAVR, were not sys-
tematically reported by authors (Table 4). However, con-
sidering that this technique is in its infancy, systematic
reports of such complications (present or not) are strongly
recommended to provide a complete understanding of the
risks associated with TAVR procedures.
In-hospital, 30-day, and 1-year follow-up outcomes.
The device success rate of the current pooled analysis
appears to be lower than previously reported. This difference
is mostly explained by the fact that VARC uses stricter
definitions, with echocardiography-derived criteria not used
before, such as AVA 1.2 cm2 and residual moderate to
severe prosthetic valve aortic regurgitation. Indeed, Gur-
vitch et al. (22) reported a relatively low success rate of 80%
using VARC definitions and explained that the main
reasons for “device failure” were a calculated AVA of 1.2
s. VARC  Valve Academic Research Consortium.nalysicm2, a criterion that may not be reasonable for either a small
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Outcomes After TAVR Using VARC Definitions June 19/26, 2012:2317–26annulus or low body weight patients. Despite this low
success rate, clinical and symptomatic improvement in these
patients was dramatic, with 97% of patients with procedural
AVA 1.2 cm2 improving to New York Heart Association
functional class I or II. Ikeda et al. (35) also reported some
concerns with the 1.2 cm2 criterion for device success,
specially in small body size populations, such as Asian
atients, in whom an indexed valve area may be more
ppropriate. Until now, no evidence has been shown that
atients with an AVA 1.2 cm2 after TAVR have a worse
outcome. Conversely, Ewe et al. (36) recently showed that
patients with prosthesis–patient mismatch after TAVR,
defined as an indexed effective orifice area 0.85 cm2/m2,
had a slower and smaller reduction in mean transaortic
gradient, limited left ventricular mass regression, and a
higher proportion of patients not improving in New York
Heart Association functional class compared with patients
Proportion of Studies ReportingOutc mes Using Appropriate VARC DefinitionsTable 2 Proportion of S udies Report ngOutcomes Using Appropriate VARC Definitions
Device success 10/16 (62.5)
30-day mortality 15/16 (93.8)
30-day cardiovascular mortality 12/16 (75.0)
1-year mortality 7/16 (43.8)
1-year cardiovascular mortality 4/16 (25.0)
Myocardial infarction 72 h 14/16 (87.5)
Acute kidney injury 9/16 (56.3)
Bleeding 7/16 (43.8)
Transfusions 7/16 (43.8)
Vascular complications 14/16 (87.5)
Stroke at 30 days 14/16 (87.5)
Permanent pacemaker 14/16 (87.5)
Composite endpoint: safety, 30 days 6/16 (37.5)
Composite endpoint: efficacy, 1 year 2/16 (12.5)
Failure to deliver or implantation of the valve in the
correct position
10/16 (62.5)
Multiple valves implanted 9/16 (56.3)
Aortic valve area 1.2 cm2 2/16 (12.5)
Mean gradient 20 mm Hg 4/16 (25.0)
Moderate to severe aortic regurgitation 11/16 (68.8)
Valve embolization 10/16 (62.5)
Valve in valve 8/16 (50.0)
Conversion to open surgery 10/16 (62.5)
Repeat procedure for valve dysfunction 8/16 (50.0)
Unplanned cardiopulmonary bypass use 3/16 (18.8)
Coronary obstruction 7/16 (43.8)
Left ventricular perforation 3/16 (18.8)
Tamponade 6/16 (37.5)
Annulus rupture 3/16 (18.8)
Aortic dissection 2/16 (12.5)
Aortic rupture 2/16 (12.5)
Endocarditis 3/16 (18.8)
Valve thrombosis 2/16 (12.5)
Left ventricular outflow tract rupture 1/16 (6.3)
Ventral septal defect 1/16 (6.3)
Values n/N (%).
VARC  Valve Academic Research Consortium.without mismatch. Moreover, no standardized method forSeT D B
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June 19/26, 2012:2317–26 Outcomes After TAVR Using VARC Definitionsechocardiographic measurement of the left ventricular out-
flow tract diameter after TAVR has been validated. There-
fore, AVA may vary considerably, depending on where the
left ventricular outflow tract measurement is performed after
TAVR (37). These issues will be addressed in future
versions of VARC definitions.
The 30-day mortality rate in the current report is similar
to the mortality rate reported in the early registries (4,5,7,8),
reflecting the use of first-generation devices, early experi-
ence of operators, and a population of patients at high or
prohibitive risk of surgery. Interestingly, the 30-day mor-
tality rate pooled estimate of our report (7.8%; 95% CI:
5.5% to 11.1%) is similar to the 30-day predicted mortality
rate by the Society of Thoracic Surgeons score (8.7%; 95%
CI: 7.0% to 10.3%). Considering that the population of the
current report represents a mix of several approaches
(transapical, transfemoral [TF], subclavian) and different
devices, this finding underlines the high-risk profile of the
patients included in this meta-analysis.
The cardiovascular mortality rate, both at 30 days and 1
30-Day and 1-Year VARC Outcomes After TAVRTable 3 30-Day and 1-Year VARC Outcomes After TAVR
Outcome
Reported Rate Min,
Max, %
Cumulative
Rate
Device success 80.0, 100.0 1,748/1,899
30-day mortality 1.7, 14.3 258/3,465
30-day CV mortality 1.7, 11.5 142/2,645
1-year mortality 15.3, 30.7 336/1,530
1-year CV mortality 14.3, 19.6 113/800
MI 72 h 0.0, 5.6 34/3,018
AKI
I 3.2, 24.6 149/1,150
II 0.8, 5.3 29/1,150
III 1.0, 10.2 98/1,929
II-III 3.0, 15.0 93/1,275
I-II-III 6.5, 34.1 232/1,150
Bleeding
Life threatening 7.0, 25.9 207/1,350
Major 2.9, 47.0 298/1,363
Minor 3.0, 16.0 95/987
All 26.8, 77.0 408/987
Transfusion 1 U 6.3, 80.0 386/906
Vascular complications
Major 5.0, 23.3 282/2,417
Minor 5.6, 28.3 203/2,142
All 9.5, 51.6 511/2,740
Stroke 30-day
Major 0.8, 9.0 84/2,730
Minor 0.0, 1.7 12/1,450
TIA 0.0, 12.0 18/1,826
Major  minor 1.0, 6.8 68/1,706
All 1.3, 21.0 103/1,892
PPM 3.4, 50.0 396/2,914
Composite endpoint: safety at 30 days 17.0, 61.8 420/1,286
Composite endpoint: efficacy at 1 year 70.2, 72.2 209/294
AKI  acute kidney injury; CV  cardiovascular; Max maximum; MI myocardial infarction; Min
able 1.year, represents 65% of the total mortality in the presentstudy. Although such results might be expected in a popu-
lation of high-risk patients who underwent a major cardiac
procedure, some authors have challenged the clinical rele-
vance to systematically attribute unknown death to cardio-
vascular death and, consequently, its relationship to the
device and underlying aortic pathology (38). In fact, accord-
ing to the current VARC definitions, unknown deaths
should be considered as cardiovascular in origin. Although
VARC suggests the use of all-cause mortality as the primary
endpoint of choice and cardiovascular mortality as a second-
ary endpoint, ascertainment and adjudication of cardiovas-
cular death remain a challenge.
Periprocedural MI (72 h after TAVR) occurred at a
rate of 1.1% (95% CI: 0.2% to 2.0%) after TAVR in the
current analysis. Although coronary obstruction is a poten-
tial cause, other factors such as global ischemia due to
hypotension, rapid pacing, microembolism induced by device
delivery or implantation, myocardial tissue compression by the
device expansion, and direct trauma of the apex during
transapical access must also be considered. VARC proposed
Cochran’s Q
p Value
Heterogeneity Pooled Estimate Rate, % 95% CI
133.2 0.0001 92.1 88.7–95.5
61.7 0.0001 7.8 5.5–11.1
40.0 0.0001 5.6 3.7–8.3
27.6 0.0001 22.1 17.9–26.9
20.2 0.0002 14.4 10.6–19.5
117.8 0.0001 1.1 0.2–2.0
45.1 0.0001 13.3 9.8–18.0
11.3 0.02 2.7 1.5–5.3
25.9 0.0005 5.3 3.5–8.2
26.2 0.0001 7.5 5.1–11.4
76.6 0.0001 20.4 16.2–25.8
43.2 0.0001 15.6 11.7–20.7
177.2 0.0001 22.3 17.8–28.3
22.1 0.0002 9.9 6.9–14.3
257.6 0.0001 41.4 35.5–47.6
34.0 0.0001 42.6 19.8–62.4
64.1 0.0001 11.9 8.6–16.4
88.9 0.0001 9.7 6.7–14.0
176.6 0.0001 18.8 14.5–24.3
37.5 0.0001 3.2 2.1–4.8
15.4 0.03 1.0 0.5–1.9
42.1 0.0001 1.2 0.0–2.3
18.4 0.005 4.0 2.4–6.3
29.3 0.0003 5.7 3.7–8.9
323.2 0.0001 13.9 10.6–18.9
146.6 0.0001 32.7 27.5–38.8
0.3 0.58 71.1 65.6–76.0
imum; PPM  permanent pacemaker; TIA  transient ischemic attack; other abbreviations as inI2, %
93.2
74.1
72.5
78.3
85.2
88.9
91.1
64.9
73.0
80.9
94.8
86.1
96.6
81.9
98.4
85.3
81.3
88.8
92.6
70.7
54.6
83.4
67.4
72.8
95.9
96.6
0.0the use of a relatively conservative definition for MI, for which
ular; LV
1
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Outcomes After TAVR Using VARC Definitions June 19/26, 2012:2317–26the recommended biomarker is the creatine kinase-myocardial
band isoenzyme, and not troponin and clinical signs of infarc-
tion. This may explain the low rate of MI reported after
TAVR. Conversely, Rodes-Cabau et al. (39) were the first to
report the incidence and implication of troponin increase after
TAVR, in which 97% of TF patients and 100% of the
transapical patients showed some degree of troponin increase.
After multivariate analysis, a greater magnitude of troponin T
VARC: Prosthesis-Related ComplicationsTable 4 VARC: Prosthesis-Related Complications
Outcomes
Reported Rate,
Min, Max, %
Cumul
Rat
Failure to deliver or implantation of the valve in the
correct position
0.8, 5.6 79/2
Multiple valve implanted 0.6, 4.1 38/2
AVA 1.2 cm2 0.0, 9.7 30/8
Mean gradient 20 mm Hg 0.0, 2.9 11/1
Moderate to severe AR 0.0, 30.0 167/2
Valve embolization 0.0, 5.6 45/2
Valve in valve 0.0, 9.0 43/2
Conversion to open surgery 0.0, 5.6 23/2
Repeat procedure for valve dysfunction 0.0, 4.1 31/1
Unplanned CPB 0.0, 1.9 15/1
Coronary obstruction 0.0, 3.0 13/1
LV perforation 0.2, 0.8 3/7
Tamponade 0.6, 4.6 29/1
Annulus rupture 0.3, 0.8 3/5
Aortic rupture 0.8, 1.0 5/5
Aortic dissection 0.9, 1.7 5/4
Endocarditis 0.3, 1.1 5/8
Valve thrombosis 0.0, 2.7 2/3
LVOT rupture 0.6 1/1
VSD 0.6 1/1
AR aortic regurgitation; AVA aortic valve area; CPB cardiopulmonary bypass; LV left ventric
and 3.
Figure 2 30-Day Event Rates of Major VARC-Related Outcomes
AKI  acute kidney injury; CV  cardiovascular; LT  life-threatening; MI  myoca
VARC  Valve Academic Research Consortium.increase (15 times the upper normal range) was shown to be an
independent predictor of mortality at a mean follow-up of 9
months as well as a factor correlated with lesser degrees of
improvement in left ventricular ejection fraction. However, the
inclusion of troponin as a criterion for MI after TAVR is still
a matter of debate, and more data and validation are needed.
AKI was reported according to the VARC definition in 9
studies (56.3%). However, less than one-third of the authors
I2, % Cochran’s Q
p Value
Heterogeneity
Pooled
Estimate Rate, % 95% CI
53.8 19.5 0.02 3.5 2.2–5.6
62.1 21.1 0.0069 1.8 1.1–3.1
98.2 55.0 0.0001 4.8 3.0–6.6
85.2 20.2 0.0002 1.0 0.0–2.1
95.3 213.5 0.0001 7.4 4.6–10.2
85.9 63.6 0.0001 1.7 0.2–3.3
80.9 36.7 0.0001 2.3 1.3–4.5
84.1 56.7 0.0001 1.3 0.0–2.6
51.7 14.5 0.04 1.8 1.0–3.7
78.0 9.1 0.01 1.3 0.3–2.2
54.1 13.1 0.04 0.7 0.4–1.1
0.0 0.6 0.43 0.4 0.1–1.5
74.4 19.5 0.0015 2.7 1.7–4.2
0.0 0.5 0.77 0.5 0.2–1.7
0.0 0.1 0.82 0.9 0.4–2.2
0.0 0.7 0.40 1.1 0.4–2.5
0.0 1.9 0.39 0.6 0.2–1.4
93.5 15.3 0.0001 1.2 0.3–2.2
— — — 0.6 0.1–4.3
— — — 0.6 0.1–4.3
OT left ventricular outflow tract; VSD ventricular septal defect; other abbreviations as in Tables
farction 72 h after procedure; PPM  permanent pacemaker;ative
e
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proposed stage to be reported according to VARC defini-
tions. Most of the AKIs were stage I, and the frequency of
stage II/III was 7.5%. Noticeably, the rate of AKI stage I
reported in the literature was as high as 24.6% in 1 study
(Table 3). This may be explained by the low threshold
chosen by the first VARC committee, in which any increase
of 0.3 mg/dl is considered AKI stage I.
Life-threatening and major bleeding after TAVR oc-
curred in 15.6% (95% CI: 11.7% to 20.7%) and 22.3% (95%
CI: 17.8% to 28.3%), respectively (Table 3). These rates
appear higher compared with previous reports. However,
bleeding complications have been inconsistently reported
and likely even underreported in the early literature
(5,11,40,41). Among the 16 studies in our analysis, trans-
fusion rates were reported by 7 authors (43.8%), with a
pooled estimate rate of needing 1 or more transfusions after
TAVR of 42.6% (95% CI: 19.8% to 62.4%). VARC
strongly recommended reporting the rate of transfusions
after TAVR. However, Gurvitch et al. (22) previously
reported that a significant proportion of patients received
blood transfusions without an obvious source of bleeding, in
whom anemia was pre-existent or the cause of the hemo-
globin decrease was unclear. Généreux et al. (42) also
reported that among the 25% of patients who needed red
blood cells after TAVR, 57% of the transfusions given were
not directly related to the procedure (gastrointestinal bleed-
ing, genitourinary bleeding, or no obvious source). Such
findings may warrant a possible separate category in future
revised VARC criteria so that a clear distinction can be
made between procedure-related blood loss and nonproce-
dural bleeding.
Major vascular complications occurred in 11.9% (95% CI:
Figure 3 VARC-Related Publications Since Original Publication
Early after its publication in January 2011, VARC definitions were already in use and
TAVR  transcatheter aortic valve replacement; VARC  Valve Academic Research Co8.6% to 16.4) of patients in the current study. Before VARCdefinitions, vascular complications were inconsistently re-
ported, and when they were, it was mostly reported by site
and according to the investigator definitions. Moreover,
classification of severity was rarely done. Piazza et al. (5)
reported their early data using the TF approach with the
Medtronic CoreValve device with a low rate (1.9%) of
vascular complications, whereas Eltchaninoff et al. (11)
reported a much higher rate (7.5%) using the same device
and the same access route. Similarly, early studies using the
Edwards device via the TF route reported 30-day vascular
complication rates ranging from 6.3% (11) to 22.9% (8).
The TA approach has been associated with a lower rate of
vascular complications than the TF route (8,40,43).
Moreover, further clarification of the current VARC
criteria may be needed because the TF approach is moving
toward a full-percutaneous procedure. Also, inclusion of
“new” alternative access sites, such as the subclavian-axillary
artery (41,44,45) and direct transaortic access (46), should
be considered in the elaboration of new definitions.
Stroke has emerged as one of the major foci of attention
after TAVR. The major stroke rate reported in our study is
3.2% (95% CI: 2.1% to 4.8%). Interestingly, minor strokes and
transient ischemic attacks were less frequently reported, under-
lying the difficulty to adequately identify such post-procedural
events, especially in a population of elderly sick patients.
Before VARC definitions, the 30-day stroke rates had
been variably reported, ranging from 1.5% (40) to 4.2% (11)
for the Edwards device and 0% (11,47) to 10% (4) for the
Medtronic device. These were mostly self- or site-reported
results and nonadjudicated events. VARC emphasizes the
necessity to confirm the diagnosis by neuroimaging tech-
nique (computed tomography and/or magnetic resonance
imaging) and to classify the severity of stroke using conven-
nuary 2011
orated into clinical research, showing acceptance by the TAVR community.
m.in Ja
incorp
nsortiutional neurological assessment tools. VARC recommended
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stroke assessment. However, Ikeda et al. (35) suggested that
the National Institutes of Health Stroke Scale should also
be used, and the time point of the evaluations should also
cover event onset (acute phase). Given the different level of
invasiveness and pattern of recovery after surgical aortic
valve replacement and TAVR, assessment and comparison
of stroke rates between these 2 approaches has become
challenging. Early recognition of events, use of an appro-
priate scoring system (National Institutes of Health Stroke
Scale and the modified Rankin Scale), neuroimaging tools,
and adjudication by a neurology specialist will provide a
more accurate comparison of stroke frequency between
different therapies.
The permanent pacemaker insertion rate in the current
analysis is 13.9% (95% CI: 10.6% to 18.9%), resulting from
the pooling of data including both devices (Medtronic
CoreValve system and Edwards Lifesciences device). It is
generally accepted that the self-expandable CoreValve, be-
cause of its higher and longer lasting radial force as well as
the deeper implantation site in the left ventricular outflow
tract, has a higher rate of pacemaker requirement than the
Edwards valve. Current evidence shows that 20% to 30%
of patients after CoreValve implantation and 3% to 5% of
patients after Edwards valve placement will require a new
permanent pacemaker. An additional analysis was per-
formed, pooling data from centers where TAVR were done
with 1 type of device, showing similar results (Edwards
valve, 4.9% [95% CI: 3.9% to 6.2%] vs. CoreValve, 28.9%
[95% CI: 23.0% to 36.0%], p  0.0001). However, differ-
ences between operator and institution relating to the
threshold for permanent pacemaker insertion must also be
considered.
Another important focus has been the higher incidence of
paravalvular leak after TAVR compared with surgical aortic
valve replacement. The pooled estimate for residual mod-
erate or severe aortic regurgitation after TAVR was 7.4%
(95% CI: 4.6% to 10.2%) in this report. Currently, however,
there are no standardized methods to grade paravalvular
regurgitation after TAVR. Whereas the current VARC
definition suggests criteria such as jet density, jet width, and
jet deceleration time for central aortic regurgitation, para-
valvular leak assessment is based on the percentage of the
circumferential extent of paraprosthetic aortic regurgitation,
which has not been validated in a TAVR population.
Uniformity and a standardized echocardiographic definition
for paravalvular leak after TAVR is mandatory for the next
version of VARC definitions.
As mentioned earlier, many authors have not reported
composite endpoints. However, among those reporting the
30-day composite endpoint, disparity seems to exist, with
rates ranging from 17.8% to 68%. Although differences in
population risk profiles may explain a portion of this
discrepancy, correct interpretation of the hierarchical order
and use of proper echocardiographic findings are mandatory
with this composite endpoint.The 1-year safety endpoint rate was reported by 2 studies
and occurred in 70% of patients. The high rate of this
endpoint is explained by the inclusion of recurrent heart
failure requiring admission as a component of this outcome.
Although important, this component can introduce “back-
ground noise,” reflecting more on the presence of subopti-
mal heart failure management, multiple comorbidities, or
different severities of left ventricular depression, despite a
perfectly functioning valve. In a recent comment, Ikeda et
al. (35) also underlined the possible bias by each country’s
medical care setting, where thresholds for hospitalization
would vary from country to country, according to local
culture.
Study limitations. Several important limitations of the
present analysis warrant discussion. This report represents a
study-level pooled analysis of 16 TAVR articles. A patient-
level analysis would have been preferable. We pooled data
that were clearly reported in each article. Authors may not
have reported outcomes simply because they did not occur,
which may have led to some overestimation of events in our
analysis. Reported outcomes from the 16 studies were
mainly self- or site reported, with only 2 studies adequately
reporting adjudicated events (33,34). This is likely to have
contributed significantly to the high heterogeneity that is
observed in this report. Different devices and approaches
were used in the selected studies, and no systematic com-
parison of the devices or approaches has been attempted
thus far. Although unlikely, a publication bias is always
possible. The aim of this meta-analysis was to evaluate the
performance and the use of the VARC definitions among
the most recent TAVR literature. A patient-level pooled
analysis comparing the different devices and access ap-
proaches was beyond the scope of this paper.
Conclusions
VARC definitions have already been used successfully in the
literature and are being rapidly adopted by the TAVR
community. However, slight modifications are needed and
may improve their application in the future. Although
VARC definitions have brought uniformity and standard-
ization in reporting outcomes after TAVR, appropriate
recognition and ascertaining, reporting and adjudication of
outcomes should be reinforced and will ensure that TAVR
study results are a valid reflection of “real-world” clinical
events.
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